We are a Swedish biotechnology company with a global presence, offering cell culture matrices for culturing of primary cells. BioLamina is built on a scientific foundation with a legacy in matrix biology and solid experience in cell culture based research. The company was established in 2008 and was co-founded by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason. Today the company has about 20 employees spanning from production, R&D, logistics, sales and marketing. Our quality system complies with ISO 9001:2015 and both management and employees follow well-defined standard processes and agreements.
BioLamina’s Biolaminins™ are the only original full length, human, recombinant laminin cell culture substrates on the market. We are known and recognized for our premium products, competence, dedication and service and position ourselves as being in the forefront of cell culturing. Our high technology products contribute to our customer’s efficiency and scientific breakthroughs and enable them to start a new era in medical research. We offer an expansive portfolio of chemically defined and xeno-free laminin proteins for a variety of applications, including reliable expansion of pluripotent cell and differentiation and maintenance of specialized cell types, such as hepatocytes, skeletal muscle cells and different neural cells. The impact of our Biolaminin matrices on cell culture quality has been scientifically validated in many high-impact journals.
BioLamina and Novo Nordisk partner to advance stem cell based therapies for three common medical conditions
BioLamina and collaborators have partnered with Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, allowing Novo Nordisk to develop novel stem cell based therapies based on Biolaminins, human recombinant laminin cell culture matrices, developed and produced by BioLamina. The three cell therapy projects they have licensed are all based on BioLamina technology. These projects aim to treat Parkinson’s disease, heart failure and loss of vision, all severe chronic conditions.
BioLamina, Stockholm, Sweden, May 16, 2018
BioLamina launches a cell therapy grade stem cell culture matrix, Biolaminin 521 CTG, bridging discovery and clinical cell therapy
BioLamina is currently undergoing an exciting phase entering the growing cell and gene therapy reagents industry. In order to meet the growing demand for documentation and traceability required for the manufacture of cells for therapy, BioLamina has launched a cell therapy grade (CTG) laminin substrate for clinical use, Biolaminin 521 CTG.
BioLamina, Stockholm, Sweden, May 2, 2018
Ny topp till Biolamina
Efterfrågan på laminin har ökat senaste året och för att säkerställa fortsatt tillväx inom så väl produktion som logistik har bolaget nu tillsatt Anders Lindblad som ny operativ chef.
Life Science Sweden, April, 2018
BioLamina stärker ledningen för ny fas – tillsätter ny operativ chef
BioLamina är i en expansiv fas med betydande affärsmöjligheter globalt. Under det senaste decenniet har laminin kommit att bli ett efterfrågat cellodlingssubstrat både inom grundforskning såväl som för forskare och företag med terapeutisk inriktning. För att kunna säkerställa fortsatt tillväxt inom produktion, logistik och ekonomi har BioLamina rekryterat en ny operativ chef, Anders Lindblad. Anders har en gedigen bakgrund inom operativ ledning, kvalitetssäkring och regulatoriska frågor inom Life Science. Han kommer närmast från roller som COO/Administratör på Cadila Pharmaceuticals Sweden, samt egen konsult för kvalitet och projektledning inom cellterapi och närliggande områden.
BioLamina, Stockholm, Sweden, April 16, 2018
En produkt som möjliggör nya cellterapier
Drömen är på väg att bli sann. I maj lanseras BioLamina officiellt en produkt för användning i kliniska prövningar. Den har redan använts för att tillverka ett kliniskt provmaterial som testats på 6 patienter, och flera företag väntar på godkännande för att starta kliniska prövningar.
Forskningssverige, Mars, 2018
BioLamina stärker ledningen med en ny chef för marknadsföring och försäljning
BioLamina’s produkter används idag i många cellterapi-relaterade projekt och efterfrågan och försäljningen ökar kraftigt år efter år. För att möta den ökade efterfrågan har BioLamina rekryterat en ny sälj- och marknadschef, Jenny Stjernberg. Jenny kommer närmast från Miteney Biotec där hon var sälj- och marknadschef för den Nordiska och Baltiska avdelningen och har en gedigen erfarenhet av försäljning och marknadsföring av cellodlingsprodukter.
BioLamina, Stockholm, Sweden, November 29, 2017
BioLamina utlicensierar ett patent mot en miljard kronor i möjliga milestones och royalties
Forskare på Lunds universitet har, med hjälp av BioLaminas produkter, lyckats utveckla ett effektivt sätt att tillverka dopaminceller från stamceller, ett viktigt genombrott i resan mot en cellterapibehandling för personer med Parkinsons sjukdom. BioLamina har nu framgångsrikt hittat en licenstagare till detta projekt bland ett av de stora globala läkemedelsbolagen.
BioLamina, Stockholm, Sweden, September 14, 2017
Corning introduces laminin-521 cultureware products
Corning has developed Corning® PureCoat™ rLaminin-521 cultureware products for stem cell research, by combining BioLamina’s expertise in rLaminin-521 expression with Corning’s proprietary surface coating technology.
CORNING, N.Y., Corning Incorporated, April 20, 2016
BioLamina utökar globalt - tecknar flera distributionsavtal
ThermoFisher, Corning, Stem Cell Technologies och ESI-Bio, kommer nu att sälja LN521 som en del av sin cell kultiverings portfölj via sina försäljningskanaler.
BioLamina, Stockholm, February 2, 2016
Liver cell therapies closer as study reveals key to mass production
Stem cell scientists have made a key find that aids the quest to produce therapies for patients with liver damage. They have developed a new technique for growing liver cells from stem cells that is cost-effective and could be adapted for mass production of clinical grade cells.
MRC Centre for Regenerative Medicine, Edinburgh, UK, November 25, 2015
Production of recombinant laminins for ex vivo cell therapies
CEVEC and BioLamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies. First commercial CAP(R)Go-derived laminin, LN521, expected to be globally available in 2016.
Dow Jones Newswire Web, October 28, 2015
BioLamina engages Dr. Stephen Minger as Scientific Advisor
BioLamina’s long-term goal is to provide a portfolio of high quality, easy to use, products and services for primary cell culture within research, drug discovery models and cell therapy. To reach this goal, BioLamina needs to focus on the right products and deliver them with the right quality. Dr. Minger’s role will be to help direct and prioritize this work, to ensure release of quality products in a timely fashion. He will work closely with our scientists and executive management.
BioLamina, Stockholm, Sweden, September 28, 2015
Corning Announces New Agreement with BioLamina
More comprehensive and scalable culture solution made available to Corning’s global customer base.
CORNING, N.Y., September 11, 2014
BioLamina tar täten när stamcellsfältet öppnas
A new method makes it possible to culture large amounts embryonic stem cells without destroying the embryo. This method can give more than 400 kilos of stem cells in a month at the same time as it avoids any ethical issues related to stem cell research.
Life Science Sweden, January, 2014
BioLamina is recruiting three new members
The Stockholm based research company BioLamina is strengthening its position through recruting three new members: Camilla Myhre Sandberg, Anders Blom och Fredrik Mattsson.
Life Science Sweden, November, 2013
Laminin article in GEN Biotech
In this article Dr. Karl Tryggvason discuss the use of biologically relevant human recombinant laminins from BioLamina that successfully recreate specific cell niches in the cell culture dish. This enables robust cell cultivation in highly physiological microenvironments that practically solves all current technical challenges with stem cell culture.
GEN Biotech, May, 2013
BioLamina ranked as one of 24 hottest startups in Sweden
BioLamina listed as the only biotech among Sweden's 24 most promising startups in Sweden.
Veckans Affärer, April 18, 2013
BioLamina listed as Sweden's 33 most successful startups
BioLamina ranked as on of Swedens 33 hottest technology companies, 3rd year in a row.
NyTeknik, April 16, 2013
BioLamina is a company in constant development and progress, and we truly believe our strength comes from our employees. It is therefore very important for us to find people who share our vision and values, and want to be part of creating the next generation of regenerative therapies.
If you are interested in knowing more about us and what being part of the BioLamina team would mean, don’t hesitate to contact us at career@biolamina.com
Students
BioLamina is a research-based company and we know and value the knowledge that resides in the young and vital university community. Therefore, we are always open to have a dialogue with students who want and need to get “real life” practice.
